Resident core · Advanced fellow reference

Antibiotic resistance and resistant organisms

How to interpret resistance, choose treatment, and recognize when the problem is the source, the exposure, or the diagnosis.

Core 30–45 minOptional secondary teachingVersion 1.3 · Edited November 10, 2026

Advanced fellow teaching is below

Complete the resident core or jump directly to the detailed teaching and reference sections.

This lecture is intended as a supplementary resource for clinicians and trainees to review evidence and discuss clinical cases.

This lecture is intended as a supplementary resource for clinicians and trainees to review evidence and discuss clinical cases.

Use the clinical context to interpret resistance

Resident core · 30–45 minutes with discussion

A susceptibility report describes an isolate. Deciding whether it explains the illness, and whether an active drug can reach the infected site, takes clinical information.

Adult bacterial infections for residents and ID fellows. Three fictional cases anchor the core. Mechanisms, exposure, trial appraisals, salvage options, and additional cases are optional reading below the lecture.

Use the three cases for discussion. Teach the highlighted matrix patterns; consult the remaining cells as reference. The advanced section is optional and comes after the resident core.

Start with the patient

Infection?Compatible syndrome and a meaningful specimen.
Urgency?Shock, organ dysfunction, immune status.
Likely activity?Prior isolates, recent antibiotics, local data.
Source?Is there an obstruction, collection, or infected device that antibiotics alone cannot address?
Reassessment?Review cultures, narrow, and set a stop plan.

A resistant culture does not establish infection. A rectal CRE screen or a chronically positive tracheal aspirate may indicate colonization. Asymptomatic bacteriuria usually needs no antibiotic; pregnancy and endourologic procedures involving mucosal trauma are key exceptions.

In severe infection, appropriate cultures are important, but obtaining them must not delay urgent active therapy. The specific prior isolate matters: a history of NDM-producing Klebsiella is more informative than a chart label of “MDRO.” Previous results and local patterns can guide initial coverage while current testing is underway.

First question for the room: What clinical evidence would make you treat this isolate?

References 1, 5

Read the organism, mechanism, and MIC together

Susceptible does not mean interchangeable

Use the drug-specific breakpoint and infection site. A smaller MIC for another drug does not make it a better choice. SDD requires the exposure linked to that category; EUCAST “I” means susceptible with increased exposure.

A gene result is a clue

A detected carbapenemase can redirect therapy before full AST. A negative panel excludes only its targets. Multiple mechanisms may coexist; confirm the phenotype and test the intended drug.

Two distinctions do most of the work today. ESBL and inducible AmpC differ in whether cefepime is a dependable choice. KPC, NDM, and OXA-48-like enzymes differ in which beta-lactamase inhibitor works.

The colors below summarize expected activity and clinical limitations. They are not laboratory calls for an individual isolate. Antimicrobial susceptibility testing (AST), infection site, drug exposure, and the evidence for that syndrome remain separate questions.

References 1, 3, 4

How resistance mechanisms change expected activity

Antibiotics run down the rows; resistance patterns run across the columns. This is a teaching synthesis for invasive infection, not a local antibiogram or a substitute for isolate-specific AST.

Green · Expected The mechanism often leaves activity intact. The individual isolate may differ.Yellow · Conditional Suitability depends on the isolate, site, exposure, reserve status, or evidence.Red · Usually inactive / Poor fit The first describes expected loss of activity; the second describes a clinical limitation that may persist despite apparent susceptibility.

“Reserve” means activity may be present, but preserve the drug for more resistant infections. Non-beta-lactam susceptibility cannot be inferred from an ESBL or carbapenemase label. A blank qualifier never waives AST.

Gram-negative resistance patterns
AntibioticESBL-EInducible
AmpC-E
KPC-ENDM-EOXA-48-like-EDTR
Pseudomonas
CeftriaxoneUsually inactivePoor fitInductionUsually inactiveUsually inactivePoor fitUnreliableUsually inactive
Piperacillin–tazobactamPoor fitInvasive diseasePoor fitInvasive diseaseUsually inactiveUsually inactiveUsually inactiveUsually inactive
CefepimePoor fitESBL diseaseExpectedMIC-linked exposureUsually inactiveUsually inactivePoor fitUnreliableUsually inactive
Meropenem / imipenem–cilastatinExpectedExpectedUsually inactiveUsually inactivePoor fitUnreliableUsually inactive
ErtapenemConditionalLess suitable in critical illness or low albuminExpectedUsually inactiveUsually inactiveUsually inactiveUsually inactive
Ceftolozane–tazobactamConditionalReservePoor fitAmpCUsually inactiveUsually inactiveUsually inactiveConditionalAST; no KPC/MBL
Ceftazidime–avibactamConditionalReserveConditionalReserveExpectedUsually inactiveNDM aloneExpectedConditionalAST; no MBL
Meropenem–vaborbactamConditionalReserveConditionalReserveExpectedUsually inactivePoor fitInhibitor mismatchPoor fitNo added benefit
Imipenem–cilastatin–relebactamConditionalReserveConditionalReserveExpectedUsually inactivePoor fitInhibitor mismatchConditionalAST; no MBL
Aztreonam–avibactamConditionalReserveConditionalReserveConditionalAlternativeExpectedConfirm ASTConditionalAlternativePoor fitLimited activity
CefiderocolConditionalReserveConditionalReserveConditionalAlternativeExpectedConfirm ASTConditionalAlternativeConditionalAST; MBL option
TMP–SMXConditionalAST; siteConditionalAST; siteConditionalAST; siteConditionalAST; siteConditionalAST; siteUsually inactive
LevofloxacinConditionalAST; siteConditionalAST; siteConditionalAST; siteConditionalAST; siteConditionalAST; siteUsually inactive

E = Enterobacterales. AmpC column assumes a species at moderate risk for inducible AmpC, without an additional ESBL or carbapenemase. DTR = nonsusceptible to the usual antipseudomonal beta-lactams and fluoroquinolones. MBL = metallo-beta-lactamase. The NDM-E column does not apply to MBL-producing Pseudomonas.

Recognize these three patterns

ESBL versus AmpC. Carbapenems are preferred for invasive ESBL infection. For species at moderate risk of inducible AmpC, cefepime is preferred when the MIC is susceptible or susceptible-dose-dependent, the exposure matches the MIC, and no ESBL gene has been identified. This group includes E. cloacae complex, K. aerogenes, and C. freundii; the inclusion of H. alvei rests mainly on laboratory evidence.1

Why the enzyme matters. Several inhibitor combinations retain activity against KPC. In invasive NDM-producing Enterobacterales infection, aztreonam-avibactam and cefiderocol are preferred options; ceftazidime-avibactam plus aztreonam is an alternative if the fixed combination is unavailable. Ceftazidime-avibactam fits a different mechanism, OXA-48-like production. The isolate’s AST remains essential.1

Difficult-to-treat Pseudomonas. Testing the four newer agents can reveal an option that the traditional panel misses. Cefiderocol is preferred for a susceptible MBL producer. A KPC-producing isolate is also a poor fit for ceftolozane-tazobactam: tazobactam does not inhibit KPC.1

Where the site changes the answer. Piperacillin-tazobactam can be an alternative for selected ESBL complicated UTI without critical illness or bacteremia. That exception does not establish efficacy for ESBL bloodstream infection. In critical illness or hypoalbuminemia, meropenem or imipenem-cilastatin is preferred over ertapenem for invasive ESBL infection.1

Two resistant nonfermenters
AntibioticCRABS. maltophilia
Meropenem / imipenem aloneUsually inactivePartner ≠ monotherapyUsually inactive
Sulbactam–durlobactamConditionalCarbapenem partnerPoor fitNot a treatment option
CefiderocolConditionalAlternative; combinationConditionalPreferred; limited human data
TMP–SMXPoor fitNot standard therapyConditionalAST; combination
LevofloxacinPoor fitNot standard therapyConditionalAST; combination
MinocyclineConditionalAST; combinationConditionalAST; combination

CRAB = carbapenem-resistant A. baumannii. Sulbactam-durlobactam plus meropenem or imipenem-cilastatin is preferred for invasive CRAB when active. For invasive S. maltophilia, 2026 IDSA guidance favors cefiderocol monotherapy, with limited human comparative evidence; TMP-SMX, levofloxacin, and minocycline are alternative combination components.

Gram-positive resistance patterns
AntibioticMRSAVRE E. faecium
Cefazolin / oxacillinUsually inactiveUsually inactive
AmpicillinUsually inactiveConditionalOften inactive; AST
CeftarolineConditionalAST; syndromeUsually inactive
CeftobiproleConditionalAST; syndromeUsually inactive
VancomycinExpectedMonitor exposureUsually inactive
DaptomycinConditionalNo pneumoniaConditionalMIC; high dose
LinezolidConditionalSyndrome; CBCExpectedMonitor CBC

Account for the infection site

MRSA — Vancomycin or daptomycin are established bacteremia options. For pneumonia, vancomycin or linezolid; daptomycin is inactivated by pulmonary surfactant.

VRE bacteremia — Linezolid or optimized high-dose daptomycin based on the MIC and patient factors. E. faecium daptomycin SDD is dose dependent, not permission to use a routine low dose. Ampicillin susceptibility is a separate question from vancomycin resistance.

CRAB and Stenotrophomonas. Either organism can colonize the airway. A compatible pulmonary syndrome, the quality of the specimen, and evidence of invasive infection determine what the isolate means.

Matrix reviewed September 17, 2026. Teaching synthesis of IDSA AMR guidance and the linked gram-positive sources. “Expected,” “Conditional,” “Usually inactive,” and “Poor fit” describe teaching patterns. None is a measured laboratory result or a guaranteed regimen for this patient.

References 1, 3, 7, 11, 13, 14, 12

The source changes the treatment

Bladder versus kidney or blood

Nitrofurantoin is not a pyelonephritis or bloodstream drug. Oral fosfomycin is not initial treatment for pyelonephritis or sepsis and is not routine bloodstream therapy. A selected transition after active IV treatment for improving E. coli complicated UTI is a separate use discussed in the antibiotic primer. Oral transition for invasive infection requires an active drug with adequate systemic exposure.

Lung versus blood

Daptomycin can treat bacteremia but not alveolar pneumonia. A respiratory CRAB or Stenotrophomonas isolate needs a compatible syndrome before treatment. The matrix cannot distinguish a colonizer from the cause of pneumonia.

Exposure and toxicity

A susceptible dose-dependent (SDD) MIC assumes a particular exposure; changes in clearance, infusion, or infection site can change the interpretation. New confusion, myoclonus, aphasia, or seizures on cefepime warrant prompt assessment for neurotoxicity, even after renal adjustment. If cefepime neurotoxicity occurs, discontinue cefepime, provide supportive care, and assess alternative active coverage.FDA label Examples of safety monitoring include potassium, renal function, and blood counts for TMP-SMX; blood counts for linezolid; and CK for daptomycin. Vancomycin monitoring is indication-specific.

Control the source, then narrow

An abscess, an obstructed urinary tract, or an infected device can sustain infection despite active therapy. Persistent or recurrent illness raises questions about drainage, delivered exposure, and changing susceptibility. Continued double coverage needs a specific rationale once an active regimen is established.

Resistance alone does not determine duration. Base the course on the syndrome, effective treatment, clinical response, and source control. Oral step-down also requires stability, absorption, and a feasible follow-up plan.

References 1, 14, 12

Use three cases to practice treatment decisions

Case 1 · An ESBL bloodstream isolate

A patient with E. coli bacteremia from obstructed pyelonephritis is hypotensive. The isolate is ESBL-producing and reported susceptible to piperacillin-tazobactam.

What determines the immediate drug and the source intervention?

Reveal teaching point

The obstruction needs urgent decompression. In this hypotensive patient with ESBL bacteremia, active meropenem or imipenem-cilastatin is preferred even if piperacillin-tazobactam tests susceptible. Later, relief of obstruction, clinical stability, a susceptible systemic oral option, and reliable absorption may permit an oral switch. Nitrofurantoin does not provide adequate bloodstream exposure.115

Case 2 · Ceftriaxone-susceptible Enterobacter

E. cloacae complex grows in blood. Ceftriaxone and cefepime are reported susceptible.

Why is ceftriaxone susceptibility not the end of the decision?

Reveal teaching point

An initially susceptible E. cloacae complex isolate can become resistant during ceftriaxone therapy. For invasive infection, cefepime is preferred when the MIC and achievable exposure support it and no ESBL gene has been identified. A carbapenem may fit better if another mechanism undermines cefepime. The source and its control remain part of that decision.1

Case 3 · A carbapenemase result changes the plan

K. pneumoniae bacteremia is initially treated with ceftazidime-avibactam. The rapid assay detects NDM.

What should change before the complete susceptibility panel returns?

Reveal teaching point

NDM hydrolyzes ceftazidime, and avibactam does not block NDM. The current drug therefore needs prompt reassessment. For suspected invasive NDM-producing Enterobacterales infection, prior testing and available active agents guide urgent treatment while current AST is pending. Aztreonam-avibactam and cefiderocol are preferred options; ceftazidime-avibactam plus aztreonam is an alternative when the fixed product is unavailable. MBL-producing Pseudomonas is a separate problem.1

References 1

Leave with a usable plan

A useful case presentation links the syndrome to the organism, the source to the drug’s exposure, and the choice of treatment to the evidence. Source control, monitoring, the start of the treatment clock, and the next reassessment complete the explanation.

Ask learners to complete one sentence: “I am treating ___ with ___ because ___, and I will reassess ___.”

40–45 min · Questions

Use the closing discussion to revisit a case or a matrix cell. The detailed material below is for a separate discussion or independent study.

End of the resident core

Advanced fellow teaching and detailed reference

These expanded sections are outside the resident core. Choose an individual topic for a separate teaching session.

Begin with five clinical decisions before choosing a drug

Is this infection?Name the syndrome and assess specimen quality.
How urgent is it?Assess shock, organ dysfunction, and immune status.
What is likely active?Review prior isolates, recent therapy, and the local antibiogram.
Will it reach the site?Check tissue exposure, dose, route, and source control.
What changes tomorrow?Set a culture review, narrowing plan, and monitoring plan.

A resistant organism in urine, a chronic wound, or a tracheal aspirate may be colonization. A new compatible syndrome, objective findings, and the quality of the specimen determine whether treatment is warranted. A rectal CRE screen guides precautions and empiric risk assessment; it is not an indication for antibiotics.

Appropriate cultures can clarify the source but must not delay urgently needed treatment in severe infection. Prior susceptibility results, recent therapy, and local epidemiology help estimate activity while tests are pending. A prior NDM-producing isolate and a prior KPC-producing isolate imply different options even though both may be called CRE. Additional testing of a retained invasive isolate can resolve a discordant result.

Identification and susceptibility results can explain why broad empiric coverage is no longer needed. If bacteremia or fever persists, an undrained collection, urinary obstruction, or infected device may explain failure better than a gap in antibacterial spectrum.

Do not treat an asymptomatic culture

Asymptomatic bacteriuria generally does not need antibiotics, including when the isolate is ESBL-producing or VRE. Established indications include pregnancy and before endoscopic urologic procedures involving mucosal trauma. Pyuria alone does not distinguish infection from colonization. Severe systemic illness requires a clinical evaluation, not automatic dismissal as asymptomatic bacteriuria.

References 1, 5, 6

Mechanisms explain which apparently similar drugs are different

Resistance mechanisms and clinical consequences
MechanismExamplesWhat changes at the bedside
Drug destructionESBLs, AmpC, KPC, NDM, OXA enzymesThe inhibitor must match the enzyme. Ceftazidime-avibactam activity against KPC does not imply activity against NDM.
Altered targetmecA/mecC and altered penicillin-binding proteins; van genes; gyrase mutationsMRSA resists usual antistaphylococcal beta-lactams. Vancomycin resistance does not independently establish ampicillin or daptomycin resistance.
Reduced entryPorin loss, including OprD in PseudomonasCarbapenem resistance can coexist with cefepime susceptibility. Not every carbapenem-resistant isolate produces a carbapenemase.
Active drug effluxPseudomonas and Stenotrophomonas efflux systemsMultiple classes can be affected; a single enzyme result cannot fully predict the phenotype.
Multiple mechanisms togetherESBL or AmpC plus porin loss; NDM plus other beta-lactamasesA phenotype may require more than one explanation. Repeat susceptibility testing when infection recurs after treatment.

Intrinsic resistance and biofilm are different problems

Enterococci are intrinsically resistant to cephalosporin monotherapy. Ertapenem does not cover Pseudomonas or Acinetobacter. Stenotrophomonas is intrinsically resistant to carbapenems. Biofilm-associated persistence may occur despite a susceptible MIC because routine testing evaluates planktonic organisms; investigate the infected surface or device.

ESBL and AmpC describe beta-lactamases. CRE describes a resistance phenotype or carbapenemase production. KPC and NDM identify mechanisms. MDR describes resistance across several categories. DTR Pseudomonas means nonsusceptibility to all eight traditional agents listed in the Pseudomonas section. These terms are related but not interchangeable.

References 1, 7, 3

Read the susceptibility report as a conditional prediction

Interpretation pitfalls
ReportInterpretationAction
A lower MIC for drug A than drug BMIC numbers across different antibiotics are not a potency ranking. Breakpoints and achievable exposures differ.Compare each result with the applicable organism, site, and dosing breakpoint.
Susceptible dose-dependent (SDD)The category assumes a specified higher exposure. It is not standard-dose susceptibility.Ask which regimen supports the result. Cefepime MIC 4-8 micrograms/mL in Enterobacterales is SDD under the cited 2026 criteria.
EUCAST “I”EUCAST defines I as susceptible with increased exposure. It is not interchangeable with the CLSI intermediate category.Confirm which standard your laboratory uses before interpreting an outside report.
CTX-M detectedSupports an ESBL mechanism in the organism carrying the gene.The likely mechanism can inform initial coverage while susceptibility testing is pending. A negative CTX-M result does not exclude other ESBLs or AmpC.
Carbapenemase panel negativeOnly the targets on that panel were excluded. Porin/efflux mechanisms and untested enzymes remain possible.Reconcile with the phenotype; obtain broader phenotypic or reference-laboratory testing for discordance.
Drug not listedMay reflect selective reporting, no routine test, or lack of validated breakpoints.Ask for the actual MIC, method, interpretation, and additional testing. Do not assume susceptibility or resistance.
Susceptible but poor site exposureIn vitro activity is insufficient if exposure at the infected site is inadequate.Avoid nitrofurantoin for pyelonephritis or bacteremia and daptomycin for alveolar pneumonia.

For presumed ESBL in E. coli, K. pneumoniae, or K. oxytoca, the 2026 IDSA document uses ceftriaxone MIC at least 4 micrograms/mL as a surrogate. This is not molecular confirmation and is not a universal rule for every Enterobacterales species. In mixed cultures, confirm which organism carries a detected resistance gene.

Ask specifically about newer beta-lactam testing for CRE or DTR Pseudomonas, combination testing when using ceftazidime-avibactam plus aztreonam, and reliable cefiderocol testing. A breakpoint for one species or formulation must not be borrowed for another. Oral and IV fosfomycin have different interpretive criteria.

References 1, 3, 4

Why an ESBL urinary isolate and an ESBL bloodstream isolate can lead to different choices

ESBL treatment by syndrome
SyndromePractical choiceImportant limits
Bladder-only infectionNitrofurantoin or TMP-SMX when active and appropriate. The 2026 guidance also includes single-dose aminoglycoside, gepotidacin, pivmecillinam, and oral sulopenem-probenecid among preferred options.Check patient eligibility, availability, interactions, and susceptibility. U.S. uncomplicated UTI labels specify susceptible organisms and female patients. Gepotidacin is labeled from age 12 and 40 kg. Pivmecillinam is labeled for adults, and sulopenem-probenecid for adults with limited or no alternative oral options.FDA labels Fosfomycin is an alternative for E. coli cystitis. Do not extrapolate a bladder regimen to febrile or invasive disease.
Pyelonephritis / cUTISusceptible TMP-SMX, ciprofloxacin, or levofloxacin. If unsuitable, a carbapenem or cefepime-enmetazobactam.IV fosfomycin, aminoglycosides, and piperacillin-tazobactam are alternatives in the 2026 guidance. The piperacillin-tazobactam alternative applies only in the absence of critical illness and concomitant bacteremia.
Bacteremia, pneumonia, or other invasive infectionA carbapenem is preferred. Meropenem or imipenem-cilastatin is preferred over ertapenem in critical illness or hypoalbuminemia because ertapenem exposure is less predictable.Ertapenem can be useful in stable patients with appropriate pharmacokinetics and source control. Cefepime-enmetazobactam is an alternative; invasive ESBL outcome data are less established.
Oral transition after improvementActive TMP-SMX or a fluoroquinolone, after hemodynamic stability, source control, and confirmation of absorption.For bloodstream infection, do not use nitrofurantoin or oral fosfomycin as completion therapy. An ESBL label does not itself mandate a PICC.

Avoid plain cefepime for ESBL pyelonephritis/cUTI or invasive disease even when it reports susceptible. Cefepime-enmetazobactam is a distinct combination with a different role. Piperacillin-tazobactam is not preferred for ESBL bacteremia; MERINO failed to establish noninferiority to meropenem.

Fosfomycin needs a formulation and a site

Oral fosfomycin is principally a cystitis option for E. coli. The 2026 guidance permits selected oral transition use after initial improvement in E. coli cUTI when other oral options are unavailable, with limited supporting evidence. This is not initial therapy for pyelonephritis, nor reliable bacteremia therapy. IV fosfomycin is a separate alternative for cUTI with different dosing, susceptibility criteria, and sodium burden.

References 1, 15, 16, 3

Species-level identification helps predict resistance emerging during treatment

Enterobacter cloacae complex, Klebsiella aerogenes, and Citrobacter freundii have clinically important inducible AmpC risk. The 2026 guidance adds Hafnia alvei, supported mainly by laboratory data and limited clinical experience. A ceftriaxone-susceptible initial isolate can become resistant during therapy.

For invasive infection caused by these moderate-risk species, cefepime is a preferred option when the isolate tests susceptible or SDD, the regimen supports that exposure, and no ESBL gene has been identified. Cefepime resistance or an identified ESBL may favor a carbapenem. Piperacillin-tazobactam is not suggested for invasive disease caused by this group.1

Do not apply an old “SPICE” mnemonic uniformly. Serratia marcescens, Morganella morganii, and Providencia species have a lower likelihood of clinically significant AmpC overexpression; generally follow susceptibility testing. In high-burden infection or inadequate source control, cefepime may still be preferred. C. koseri is not C. freundii, and K. pneumoniae is not K. aerogenes.

When empiric ceftriaxone has already been started

Ceftriaxone is generally unsuitable as planned treatment of invasive infection caused by these moderate-risk species. Finishing a course that began empirically with ceftriaxone is a narrow exception in nonsevere infection after clear clinical improvement and adequate source control. Shock, an undrained collection, and an endovascular focus do not fit that exception.

References 1, 3

Why the carbapenemase changes which inhibitor can work

Definitive therapy for invasive CRE with demonstrated activity
Mechanism or phenotypePreferred approachAvoid the shortcut
KPCMeropenem-vaborbactam, ceftazidime-avibactam, or imipenem-cilastatin-relebactam. IDSA slightly favors meropenem-vaborbactam, followed by ceftazidime-avibactam and then imipenem-cilastatin-relebactam.1This preference is not based on a head-to-head randomized trial. Prior exposure and new MICs matter.
NDM / other metallo-beta-lactamaseFor NDM, aztreonam-avibactam or cefiderocol. If aztreonam-avibactam is unavailable, ceftazidime-avibactam plus aztreonam is an alternative. For VIM/IMP, confirm organism-specific testing and specialist interpretation.Ceftazidime-avibactam alone, meropenem-vaborbactam, and imipenem-relebactam do not solve an MBL mechanism.
OXA-48-likeCeftazidime-avibactam is preferred. Cefiderocol and aztreonam-avibactam are alternatives. Eravacycline and tigecycline are alternative options outside bloodstream and urinary tract infections.1Vaborbactam and relebactam do not reliably inhibit OXA-48-like enzymes, even if an isolated susceptible report appears reassuring.
No carbapenemase; ertapenem nonsusceptible but meropenem and imipenem susceptibleWhen testing confirms this non-carbapenemase phenotype, extended-infusion meropenem or imipenem-cilastatin can provide active exposure.Ertapenem resistance alone does not mean all carbapenems are inactive.
No carbapenemase; all carbapenems nonsusceptibleA susceptible newer beta-lactam/beta-lactamase inhibitor, selected with microbiology and ID.Do not escalate the dose of an inactive carbapenem and presume the resistance is overcome.

Aztreonam survives MBL hydrolysis, but co-produced serine beta-lactamases can destroy it. Avibactam protects aztreonam from those accompanying enzymes. Avibactam does not inhibit NDM itself. This explains why the combination can work when aztreonam alone and ceftazidime-avibactam alone do not.

Do not routinely add an aminoglycoside or polymyxin once an active beta-lactam regimen is established. Tigecycline and eravacycline are alternatives only for suitable nonbloodstream, nonurinary sites. They are poor choices for CRE bacteremia or UTI.

Guidance use and the US label are not identical

The U.S. aztreonam-avibactam indication is adult complicated intra-abdominal infection with limited or no alternatives, in conjunction with metronidazole.10 Its preferred role for NDM-producing Enterobacterales bacteremia is guidance-supported and off-label. It is not established as superior to cefiderocol in a head-to-head trial.1

References 1, 10

Carbapenem resistance in Pseudomonas does not automatically require a reserve antibiotic

If cefepime, ceftazidime, piperacillin-tazobactam, or aztreonam remains susceptible, an optimized traditional beta-lactam may be appropriate even when carbapenems are resistant. In critical illness or poor source control, a susceptible newer agent is also reasonable. OprD loss can disproportionately affect carbapenems; this is one reason to interpret the complete pattern.

DTR Pseudomonas is nonsusceptible to all eight traditional options in its definition: piperacillin-tazobactam, ceftazidime, cefepime, aztreonam, meropenem, imipenem, ciprofloxacin, and levofloxacin. Testing ceftolozane-tazobactam, ceftazidime-avibactam, imipenem-relebactam, and cefiderocol addresses a different question: does an active newer agent remain?

DTR Pseudomonas by clinical context
ContextTreatment approach
Infection outside the urinary tract, with no carbapenemase identifiedCeftolozane-tazobactam, ceftazidime-avibactam, or imipenem-relebactam when active. Cefiderocol is an alternative.
PneumoniaCeftolozane-tazobactam is preferred for susceptible DTR Pseudomonas pneumonia, except when KPC or an MBL has been identified. A pneumonia preference does not imply superiority at every site.
cUTI without an identified carbapenemaseAll four newer agents are preferred options when active, including cefiderocol. Once-daily amikacin or tobramycin may be alternatives with pharmacokinetic monitoring.
KPC-producing PseudomonasPreferred if active: cefiderocol, ceftazidime-avibactam, or imipenem-relebactam. Select by susceptibility testing.
MBL-producing PseudomonasCefiderocol preferred when susceptible. Aztreonam-avibactam has limited activity here; do not transfer the NDM Enterobacterales algorithm to Pseudomonas.
Recurrence after a newer beta-lactamObtain new cultures and repeat susceptibility testing. Cross-resistance can emerge, including between ceftolozane-tazobactam and ceftazidime-avibactam.

Once a beta-lactam is confirmed active, routine continued combination therapy is not suggested. Aminoglycoside monotherapy is unsuitable for invasive nonurinary disease. Routine adjunctive inhaled antibiotics are not suggested for DTR Pseudomonas pneumonia. The 2026 guidance permits specialist-selected adjunctive use when no newer beta-lactam is active and systemic treatment gives a suboptimal response. There is no demonstrated survival benefit; bronchoconstriction and other pulmonary toxicity matter.

References 1

When a carbapenem-resistant Acinetobacter isolate explains the illness

CRAB refers here to carbapenem-resistant Acinetobacter baumannii complex. A respiratory or wound isolate can represent colonization. In a seriously ill patient with a compatible invasive syndrome, organism-specific susceptibility testing informs definitive therapy but need not delay initial active treatment.

For invasive CRAB, the preferred combination is sulbactam-durlobactam with imipenem-cilastatin or meropenem. Sulbactam acts directly on Acinetobacter; durlobactam protects it from certain beta-lactamases. The carbapenem is a partner in this combination, not evidence that it works alone. The U.S. sulbactam-durlobactam label covers adults with hospital-acquired or ventilator-associated bacterial pneumonia due to susceptible A. baumannii-calcoaceticus complex. Other infection sites are outside that indication.117

If sulbactam-durlobactam cannot be obtained immediately, high-exposure ampicillin-sulbactam with another active agent has a temporary bridging role. The relevant amount is the sulbactam component, not the combined product weight. This is a contingency while the preferred drug is being obtained, not an equivalent definitive regimen.

If sulbactam-durlobactam resistance or an MBL is identified, obtain specialist guidance for a nonsulbactam combination using available active agents such as cefiderocol, minocycline, or polymyxin B. The optimal salvage regimen is uncertain. Do not generalize OXA-48 Enterobacterales treatment to Acinetobacter OXA carbapenemases.

What ATTACK established

Sulbactam-durlobactam plus imipenem-cilastatin met a prespecified noninferiority endpoint against colistin plus imipenem-cilastatin, with substantially less nephrotoxicity. The mortality confidence interval included no difference. The study does not establish a mortality superiority claim, and most patients had pneumonia.

References 1, 17, 2

Stenotrophomonas treatment requires an explicit assessment of the evidence

First determine whether a respiratory isolate represents infection. Carbapenem exposure can select Stenotrophomonas, and meropenem does not treat it. Invasive disease includes clinically established pneumonia, bloodstream infection, and other deep infection; a positive airway culture alone is insufficient.

Why the preference for cefiderocol is qualified

For established invasive S. maltophilia infection, cefiderocol alone is the preferred approach when active. That preference draws heavily on susceptibility, drug-exposure data, and animal models; comparative human studies have not established superior outcomes.1

Alternative approaches include aztreonam-avibactam preferably with a second agent, or combination regimens incorporating active TMP-SMX, levofloxacin, or minocycline. Ceftazidime-avibactam plus aztreonam is an alternative when aztreonam-avibactam is unavailable. Selection depends on the site, susceptibility, toxicities, and access. Do not present TMP-SMX monotherapy as the current default for invasive disease.

After clear and sustained improvement, transition to a single active oral alternative may be considered with specialist review. Minocycline has limited sustained serum exposure and is a poor initial monotherapy choice for bacteremia. Levofloxacin can select resistance during treatment. Monitor potassium, renal function, and CBC with TMP-SMX.

Use current testing criteria. The cited minocycline susceptible breakpoint is at most 1 microgram/mL. Aztreonam-avibactam has no established CLSI or FDA breakpoint for Stenotrophomonas in the retrieved guidance. Do not assign “susceptible” by borrowing the Enterobacterales cutoff.

References 1, 3

MRSA and VRE require different treatment decisions at different infection sites

Resistant gram-positive organisms
Organism and siteTreatment frameworkWhat must accompany the drug
MRSA bacteremia / endovascular infectionVancomycin or daptomycin are established options. Ceftobiprole is another option for adult S. aureus bacteremia within its approved indication; assess availability and trial applicability.Follow-up cultures, source control, evaluation for endocarditis and metastatic infection, and a syndrome-specific duration.
MRSA alveolar pneumoniaVancomycin or linezolid.Daptomycin is inactivated by pulmonary surfactant. Drain empyema when present. Oral bioavailability alone does not establish suitability for an unstable patient.
Purulent MRSA skin infectionDrain an abscess; add a susceptible oral agent such as TMP-SMX or doxycycline when systemic treatment is indicated, or IV therapy for severe disease.If accompanying nonpurulent cellulitis needs streptococcal coverage, ensure the regimen provides it. Clindamycin requires attention to inducible resistance testing.
VRE E. faecium bacteremiaLinezolid or high-dose daptomycin selected by susceptibility, site, organ function, and toxicity. Daptomycin use for VRE is off-label.Confirm species, actual daptomycin MIC, source control, and clearance. The exposure assumption for E. faecium differs from that for S. aureus bacteremia.
Vancomycin-resistant but ampicillin-susceptible enterococcusAmpicillin may remain useful; an endovascular infection needs a syndrome-specific regimen.Vancomycin resistance does not rule out all beta-lactams. Cephalosporin monotherapy does not treat enterococci.
VRE in urine without symptomsUsually no antibiotic.Apply the asymptomatic bacteriuria framework. For symptomatic cystitis, consider a susceptible urinary agent; for pyelonephritis or bacteremia, use systemic therapy.

For E. faecium, a daptomycin MIC of 4 micrograms/mL falls in the CLSI susceptible dose-dependent category (≤4 micrograms/mL). This category assumes increased daptomycin exposure. The linked FDA breakpoint rationale gives the underlying dosing assumption; recognizing a breakpoint does not establish an approved VRE regimen. An MIC of 4 in another enterococcal species has a different interpretation. Confirm the laboratory standard before prescribing. FDA recognition of CLSI SDD criteria.

For serious MRSA infection, national vancomycin guidance favors AUC-guided dosing, generally AUC24/MIC 400-600 when MIC is assumed to be 1 mg/L. Some services use pharmacy-directed trough monitoring. Confirm the treating service’s approach, target, draw timing, and creatinine monitoring; do not equate a single trough with an AUC.

For adult S. aureus bacteremia without a deep or metastatic focus after adequate evaluation, the usual duration is 14 days from blood-culture clearance. If the focus is removed later, that later date may be the starting point. Persistent bacteremia or an incomplete evaluation may justify a longer course. Endocarditis, osteomyelitis, and retained infected devices require separate assessment. Methicillin resistance alone does not establish the duration.8

Persistent bacteremia is a diagnostic problem as well as a treatment problem

Reassess lines, valves, devices, undrained collections, dosing, and repeat susceptibilities. Daptomycin plus a beta-lactam may be considered as specialist salvage for selected persistent MRSA or VRE infections. Routine upfront combination therapy is not established for every patient; the partner beta-lactam may be intended for synergy rather than independent susceptibility.

References 7, 9, 8, 18, 5, 11

What an exposure-dependent result means

Why the MIC alone is incomplete. A susceptible dose-dependent result assumes a defined level of drug exposure. Renal clearance, infusion duration, and reliable delivery can change whether the patient reaches it.

The adult regimens linked below assume normal organ function unless specified. Renal replacement, changing clearance, CNS infection, pregnancy, pediatric care, and home infusion may require a different reference or delivery plan.

What can make an apparently active regimen unreliable?
ExampleWhy exposure mattersWhat changes the interpretation
Cefepime or a carbapenemFor selected susceptible gram-negative isolates, prolonged infusion helps sustain exposure above the MIC. It cannot reverse demonstrated resistance.Renal function and the infection site affect the regimen. New encephalopathy, myoclonus, or seizures during cefepime treatment warrant prompt evaluation.
Fixed beta-lactam/inhibitor combinationsThe total product amount is not the amount of either component. Separate aztreonam plus ceftazidime-avibactam is also a different regimen from fixed aztreonam-avibactam.Product, formulation, renal function, and delivery method distinguish these regimens. The U.S. aztreonam-avibactam indication for complicated intra-abdominal infection includes concurrent metronidazole.
Cefiderocol or sulbactam-durlobactamBoth reduced and unusually rapid renal clearance can alter the exposure delivered by a given regimen.The agent-specific reference describes adjustments. In invasive CRAB, the carbapenem partner of sulbactam-durlobactam serves a different purpose from independent carbapenem activity.
Linezolid or daptomycin for VRELinezolid exposure can be achieved orally or intravenously; daptomycin susceptibility in E. faecium depends on the exposure underlying the breakpoint. Daptomycin treatment for VRE is off-label.At least weekly CBC monitoring accompanies linezolid; daptomycin requires CK and renal monitoring, with closer follow-up when risk is higher. New muscle symptoms or respiratory findings warrant assessment.
TMP-SMXDrug amounts are expressed by the trimethoprim component. A lower-tract regimen does not establish exposure for an invasive infection.Potassium, renal function, blood counts and interacting medications may limit treatment.

An infusion plan that works in hospital may fail at home if line access, product stability, or the pump cannot support it. The adult dosing reference and the relevant product labeling specify regimens; pharmacy assessment addresses the individual patient and delivery setting. A prolonged infusion must not delay adequate initial treatment of severe infection.

References 2, 10, 18, 12, 14

Clinical failure should trigger a structured reassessment

When the patient is not improving
QuestionWhat to look for
Was the original diagnosis correct?Colonization, drug fever, inflammatory disease, malignancy, or a second untreated infection.
Is the source controlled?Obstruction, abscess, empyema, infected catheter, endocarditis, prosthesis, or other retained focus.
Was active exposure actually delivered?Missed doses, overly reduced renal dosing, rising clearance, poor absorption, chelation interactions, line problems, or inadequate site penetration.
Has resistance changed?Repeat cultures and AST from clinically relevant specimens; compare with baseline and prior exposure.
Is treatment causing harm?AKI, cefepime neurotoxicity, TMP-SMX hyperkalemia, linezolid cytopenia, daptomycin toxicity, or C. difficile infection.

Resistance alone does not require a longer course. Use the infection syndrome, source control, host, and response to choose duration. For invasive infection initially treated with an inactive drug, reassess the treatment clock from effective therapy. S. aureus bacteremia has clearance-based duration rules. A bladder infection that has already clinically resolved may not need a new course solely because the final report shows resistance to empiric therapy.

An oral transition requires an active oral drug with appropriate systemic/site exposure, stability, source control, and reliable absorption. Fluoroquinolones and TMP-SMX can allow oral completion in selected resistant Enterobacterales infections. That principle does not automatically validate oral treatment for endocarditis, CNS infection, or every resistant bacteremia.

Tell infection prevention promptly about newly identified CRE or other targeted resistance. Follow local contact-precaution and containment procedures, communicate colonization/infection status during transfer, and preserve hand hygiene, equipment cleaning, and device prevention practices. Antibiotics are not routine decolonization treatment for CRE.

References 1, 8, 6

The major studies support specific decisions within specific populations

MERINO supports carbapenems for invasive ESBL-type infection

Randomized, open-label noninferiority trial in ceftriaxone-resistant E. coli or K. pneumoniae bloodstream infection. In the primary population, 30-day mortality was 23/187 (12.3%) with piperacillin-tazobactam and 7/191 (3.7%) with meropenem. The risk difference was 8.6 percentage points; the one-sided 97.5% CI upper bound was 14.5%, exceeding the 5% noninferiority margin. Susceptibility-testing limitations and standard infusions complicate interpretation. The study does not answer bladder-only infection or prove all optimized piperacillin-tazobactam regimens equivalent to the studied regimen.

References 15

ALLIUM supports cefepime-enmetazobactam for cUTI

Randomized trial with 1,034 treated adults. In the primary analysis set, combined clinical cure and microbiological eradication occurred in 273/345 (79.1%) with cefepime-enmetazobactam and 196/333 (58.9%) with piperacillin-tazobactam. The adjusted difference was 21.2 percentage points (95% CI 14.3-27.9), meeting noninferiority and superiority criteria. This composite is not a mortality endpoint. The study did not compare cefepime-enmetazobactam with a carbapenem and does not establish superiority for ESBL bacteremia.

References 16

ATTACK supports a safer preferred CRAB regimen

Randomized phase 3 noninferiority study; 125 patients in the primary CRAB analysis, predominantly pneumonia. Both groups received imipenem-cilastatin. Day-28 mortality was 12/63 (19.0%) with sulbactam-durlobactam versus 20/62 (32.3%) with colistin, difference -13.2 percentage points (95% CI -30.0 to 3.5). The noninferiority margin was 20 percentage points. Nephrotoxicity was substantially less frequent with sulbactam-durlobactam. The wide interval and comparator limit claims about mortality superiority and other infection sites.

References 17

VRE dosing evidence is observational

In a retrospective VA cohort of 911 patients with VRE bacteremia treated with daptomycin, only 60 were in the study’s high-dose group (at least 10 mg/kg). Standard-dose treatment was associated with poorer survival after adjustment (adjusted hazard ratio 2.58, 95% CI 1.27–4.88). The threshold identifies the study group; it does not establish an optimal dose. Treatment selection, residual confounding, and incomplete MIC data limit inference. The cohort did not compare daptomycin with linezolid.18

References 18

A guidance preference is not a comparative trial result

The 2026 cefiderocol preference for invasive Stenotrophomonas rests heavily on preclinical evidence, with small and inconsistent human datasets. Similarly, choices among newer CRE agents frequently rely on mechanism, PK/PD, and observational outcomes. When teaching these choices, state the evidence limitation rather than converting “preferred” into “proven superior.”

Eight cases in which the same laboratory result could lead to different decisions

Pause before opening each discussion. Name the next action, drug choice, and information still missing.

Case 1 · A resistant urine culture without symptoms

A stable, nonpregnant adult with a chronic urinary catheter has ESBL E. coli in urine obtained for odor. There is no new urinary symptom, fever, hemodynamic change, or planned invasive urologic procedure.

Discuss the decision

With no compatible symptoms, pregnancy, or planned procedure involving mucosal trauma, the culture is consistent with asymptomatic bacteriuria. Odor and an ESBL result do not establish a treatment indication. The reason for the catheter remains a separate question.5

References 5

Case 2 · ESBL bacteremia with a susceptible piperacillin-tazobactam report

A patient with fever, hypotension, an obstructing ureteral stone, and E. coli bacteremia has CTX-M detected. Piperacillin-tazobactam is reported susceptible.

Discuss the decision

Hypotension and bacteremia make this an invasive infection, and the obstructed collecting system needs urgent decompression. Meropenem or imipenem-cilastatin is preferred if active; a susceptible piperacillin-tazobactam report does not outweigh the bloodstream outcome evidence. A later oral switch depends on recovery, source control, absorption, and an active drug with systemic exposure.151

References 15

Case 3 · Enterobacter initially susceptible to ceftriaxone

E. cloacae complex grows from blood and an undrained intra-abdominal collection. Ceftriaxone is susceptible; cefepime MIC is 2 micrograms/mL.

Discuss the decision

The undrained collection needs source control. At the stated MIC, cefepime can be a preferred option for this moderate-risk AmpC species when the needed exposure is achievable and no ESBL gene has been identified. A carbapenem may fit better with an additional resistance mechanism. Mixed intra-abdominal infection may also require anaerobic coverage. Bacteremia with an undrained focus does not meet the exception for completing empiric ceftriaxone.1

References 1

Case 4 · NDM changes the CRE choice

A bloodstream K. pneumoniae isolate carries NDM. Ceftazidime-avibactam was started before molecular results.

Discuss the decision

Avibactam does not inhibit NDM, so ceftazidime-avibactam alone is inadequate. For this invasive Enterobacterales infection, aztreonam-avibactam and cefiderocol are preferred options pending confirmation of activity; the fixed product’s use for bacteremia falls outside its U.S. label. If it is unavailable, ceftazidime-avibactam plus aztreonam is an alternative. Source control and repeat assessment remain important.110

References 1

Case 5 · Carbapenem-resistant Pseudomonas still has an older option

A stable patient with a drained source has Pseudomonas resistant to meropenem but susceptible to cefepime.

Discuss the decision

Meropenem resistance alone does not establish DTR Pseudomonas or identify a carbapenemase. The retained cefepime susceptibility, clinical stability, and drained source make cefepime a reasonable option if the needed exposure is achievable.

References 1

Case 6 · CRAB in a ventilated patient

New fever, purulent secretions, a new infiltrate, and rising oxygen requirements accompany a CRAB respiratory isolate.

Discuss the decision

Unlike an isolated positive airway culture, the new infiltrate, hypoxemia, fever, and purulent secretions support pneumonia. Specimen quality and competing causes still matter. For clinically established invasive CRAB infection, sulbactam-durlobactam with meropenem or imipenem-cilastatin is preferred; urgent treatment need not wait for isolate-specific AST. The final result can change that choice.1

References 1

Case 7 · Stenotrophomonas after broad-spectrum therapy

A neutropenic patient has compatible pneumonia and S. maltophilia in blood and respiratory cultures.

Discuss the decision

Concordant blood and respiratory isolates together with the compatible pneumonia support invasive disease; urgent treatment is warranted. The lung and any intravascular catheter are possible sources. Active cefiderocol monotherapy is preferred, largely on preclinical evidence. There is no definitive comparative human trial establishing superiority; alternatives have different combination and toxicity considerations.1

References 1

Case 8 · VRE with daptomycin MIC 4

A patient has VRE E. faecium bacteremia, daptomycin MIC 4 micrograms/mL, and preserved renal function.

Discuss the decision

For E. faecium, this MIC is susceptible dose-dependent under CLSI criteria. It is not a routine susceptible result for S. aureus. Linezolid and higher-exposure, off-label daptomycin are distinct options. Blood counts, CK, renal function, culture clearance, and possible endovascular infection help distinguish them and guide follow-up. Persistent bacteremia raises questions about both source control and changing susceptibility.1318

References 18

Use these questions to check the reasoning

1. Does the smallest MIC identify the best antibiotic?

Show explanation

No. Compare the drug-specific breakpoint, achievable exposure, site, and outcomes evidence.

2. Does a negative CTX-M result exclude ESBL?

Show explanation

No. Other ESBL families and other resistance mechanisms can produce a similar phenotype.

3. Which Enterobacterales should make you question ceftriaxone despite initial susceptibility?

Show explanation

E. cloacae complex, K. aerogenes, and C. freundii carry moderate risk of inducible AmpC; H. alvei is included chiefly on laboratory evidence. Completing empiric ceftriaxone is a narrow exception for nonsevere infection after improvement and adequate source control.

4. Why can aztreonam-avibactam work against NDM?

Show explanation

Aztreonam resists MBL hydrolysis; avibactam blocks accompanying serine beta-lactamases. Avibactam does not inhibit NDM.

5. Can you use the NDM Enterobacterales algorithm for MBL Pseudomonas?

Show explanation

No. Cefiderocol is preferred when susceptible for MBL Pseudomonas; aztreonam-avibactam has limited activity.

6. Does every CRE infection require two independently active drugs?

Show explanation

No. An active beta-lactam for CRE generally does not benefit from an additional aminoglycoside or polymyxin, which can add toxicity. For NDM-producing Enterobacterales, ceftazidime-avibactam plus aztreonam is a mechanistic pairing when fixed aztreonam-avibactam is unavailable: avibactam protects aztreonam from accompanying serine beta-lactamases.

7. Is TMP-SMX monotherapy the 2026 default for invasive Stenotrophomonas?

Show explanation

No. Cefiderocol monotherapy is preferred in the current guidance, with explicitly limited human comparative evidence. TMP-SMX is an alternative component of combination therapy.

8. Can nitrofurantoin complete treatment of ESBL bacteremia from a urinary source?

Show explanation

No. Urinary activity does not provide adequate bloodstream exposure.

9. Does MRSA pneumonia respond to daptomycin?

Show explanation

Daptomycin should not be used for alveolar pneumonia because pulmonary surfactant inactivates it.

10. What laboratory monitoring must accompany TMP-SMX?

Show explanation

Potassium, renal function, and CBC, with timing based on baseline risk, dose, and treatment duration. Review interacting medications.

A useful consult plan explains why this regimen fits this patient

Suggested documentation

A useful handoff says what makes this an infection, what the isolate and mechanism explain, and whether the selected drug can reach the source. It also names any remaining collection or device, what result might change therapy, and what starts the treatment clock. If therapy continues outside hospital, who will review cultures and toxicity results, and is the planned route actually feasible?

Before discharge, confirm drug access, infusion feasibility, laboratory follow-up, result ownership, and the responsible clinician. A theoretical active agent that is not available or not administered is not an effective treatment plan.

Sources distinguish clinical evidence, guidance, and product labeling

Original sources accessed September 16, 2026; AMR guidance rechecked September 17 for this revision. Guidance and prescribing information were checked directly where accessible. Some original trial details were verified through indexed abstracts or regulatory records because full-text retrieval was restricted. This is a focused teaching module, not a systematic review. Confirm monitoring recommendations with current site guidance before prescribing.

  1. Clinical guidance IDSA 2026 Guidance on Antimicrobial Resistant Gram-Negative Infections
  2. Dosing reference IDSA 2026 AMR Table 1, adult dosing
  3. Laboratory reference IDSA 2026 AMR Table 2, selected CLSI/FDA breakpoints and limitations
  4. FDA label Cefepime prescribing information, section 5.2
  5. FDA labels U.S. uncomplicated UTI indications for gepotidacin, pivmecillinam, and sulopenem-probenecid.
  6. Laboratory standard EUCAST definitions of S, I, and R
  7. Clinical guideline IDSA 2019 asymptomatic bacteriuria guideline
  8. Infection prevention CDC CRE infection control
  9. Clinical guideline IDSA MRSA guideline, 2011; interpret with subsequent drug approvals and 2026 SAB consensus
  10. Consensus guidance IDSA/ESCMID 2026 S. aureus bacteremia consensus, updated September 9, 2026
  11. Consensus guideline ASHP/IDSA/PIDS/SIDP vancomycin monitoring guideline, 2020
  12. US prescribing information Aztreonam-avibactam (Emblaveo) prescribing information
  13. FDA approval record FDA approval of ceftobiprole for serious infections, April 2024
  14. US prescribing information Linezolid (Zyvox) prescribing information
  15. Breakpoint interpretation FDA reevaluation recognizing CLSI daptomycin SDD criteria for E. faecium
  16. US prescribing information Daptomycin (Cubicin RF) prescribing information
  17. Randomized trial Harris et al. MERINO. JAMA 2018. doi 10.1001/jama.2018.12163
  18. Randomized trial Kaye et al. Cefepime-enmetazobactam versus piperacillin-tazobactam for cUTI. JAMA 2022
  19. Randomized trial Kaye et al. ATTACK. Lancet Infect Dis 2023. doi 10.1016/S1473-3099(23)00184-6
  20. Observational cohort Britt et al. Daptomycin dose and VRE bacteremia outcomes. Clin Infect Dis 2017;64:605-613

Antibiotic resistance · One-page rounds sheet

Teaching companion · Edited November 10, 2026. The full module explains exposure assumptions, evidence, and exceptions; the original dosing references provide regimens.

Start with infection

Name the syndrome, assess severity, review prior isolates, obtain appropriate cultures, and control the source. A resistant colonizer does not need antibiotics.

ESBL and AmpC

Carbapenems are preferred for invasive ESBL infection. For moderate-risk inducible AmpC species, cefepime is preferred at a susceptible or SDD MIC when exposure is adequate and no ESBL gene has been identified. These are different mechanisms.1

CRE mechanism

For invasive Enterobacterales infection, KPC and OXA-48-like enzymes can both be inhibited by avibactam. KPC also has meropenem-vaborbactam and imipenem-relebactam options. NDM is different: aztreonam-avibactam or cefiderocol is preferred if active; ceftazidime-avibactam plus aztreonam is an alternative if the fixed product is unavailable.1

Pseudomonas

Carbapenem resistance can coexist with susceptibility to cefepime or another traditional beta-lactam. In DTR Pseudomonas, expanded AST is needed. For KPC producers, consider active cefiderocol, ceftazidime-avibactam, or imipenem-relebactam. For MBL producers, cefiderocol is preferred when active.1

CRAB and Stenotrophomonas

A positive airway culture alone does not establish invasive infection. For invasive CRAB, sulbactam-durlobactam with imipenem-cilastatin or meropenem is preferred; urgent therapy need not wait for AST. For invasive S. maltophilia, the preference for active cefiderocol alone rests mostly on preclinical evidence.1

MRSA and VRE

Vancomycin and daptomycin are established options for MRSA bacteremia; clearance and the infected focus affect duration. Daptomycin should not be used for alveolar pneumonia. For VRE E. faecium bacteremia, linezolid and higher-exposure, off-label daptomycin have distinct MIC and toxicity considerations.131412

Exposure and toxicity

MICs are not cross-drug rankings. Match SDD to dose. Adjust for changing renal function. TMP-SMX: K+, creatinine, CBC. Linezolid: CBC. Daptomycin: CK. Cefepime: renal function and mental status.

Reassess and narrow

Repeat AST for recurrence or persistence. Recheck source control and delivered exposure. Resistance alone does not extend duration. Oral transition requires active drug, site exposure, stability, and absorption.